While RUA Life Sciences’ FY 2021 results echoed some of the challenges from last year’s pandemic, largely in the well-flagged revenue shortfall stemming from RUA’s customers that was a result of fewer elective surgeries, RUA’s focus now is on investing the proceeds of last year’s share offering in its vascular and heart valve products. Our forecasts and valuation have been updated for this increased pace of investment.
14 Jul 2021
FY 2021 Final Results – Investing in Growth
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
FY 2021 Final Results – Investing in Growth
RUA Life Sciences Plc (RUA:LON) | 10.8 0 0.0% | Mkt Cap: 6.67m
- Published:
14 Jul 2021 -
Author:
Hannah Crowe | Andy Smith -
Pages:
6
While RUA Life Sciences’ FY 2021 results echoed some of the challenges from last year’s pandemic, largely in the well-flagged revenue shortfall stemming from RUA’s customers that was a result of fewer elective surgeries, RUA’s focus now is on investing the proceeds of last year’s share offering in its vascular and heart valve products. Our forecasts and valuation have been updated for this increased pace of investment.